Thomas Stankovich - Mar 31, 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role: Chief Financial Officer
Signature: /s/ Thomas Stankovich
Stock symbol: RSLS
Transactions as of: Mar 31, 2023
Transactions value $: $26,161
Form type: 4
Date filed: 7/6/2023, 04:16 PM
Previous filing: Mar 7, 2023
Next filing: Jul 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RSLS	Common Stock, $0.001 par value per share	Sale	-$283	-109	-1.79%	$2.60	5.98K	Mar 31, 2023	Direct	F1
transaction	RSLS	Common Stock, $0.001 par value per share	Sale	-$227	-96	-1.6%	$2.36	5.89K	Apr 30, 2023	Direct	F1
transaction	RSLS	Common Stock, $0.001 par value per share	Sale	-$236	-98	-1.66%	$2.41	5.79K	May 31, 2023	Direct	F1
transaction	RSLS	Common Stock, $0.001 par value per share	Purchase	$26.9K	+17.7K	+305.84%	$1.52	23.5K	Jun 30, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.